Actelion, which manufactures treatments for conditions like pulmonary arterial hypertension (PAH), will be acquired by Johnson & Johnson for $30 billion. The board of directors of both companies agreed to the transaction, said Alex Gorsky, chairman and CEO of Johnson & Johnson. “We believe this transaction offers compelling…
News
Bayer and Merck recently presented positive results from five data sets that evaluated the clinical benefits of Adempas (riociguat) for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The findings were presented at the 11th annual World Congress of the Pulmonary Vascular…
An initial combination treatment with Tracleer (bosentan) and Ventavis (iloprost, inhalation solution) dramatically improved exercise capacity and clinical function in patients with pulmonary arterial hypertension (PAH), compared to treatment with either of those medications alone. The study, “Treatment of pulmonary arterial hypertension using initial combination therapy of…
An international study to assess clinical practices in the diagnosis and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH) found several differences in CTEPH management among regions, but also a gap between guideline procedures and real-life practice of diagnosis and treatment. The study, “An International Physician Survey of…
Pulmonary arterial hypertension (PAH) is a rare complication in hepatitis C or multiple sclerosis patients using interferon α or β therapy, but still one that’s substantially more common in these people than in the general population, suggesting a link between the therapy and PAH, researchers reported. Type I interferons, including interferon α and β, are naturally occurring compounds in the body,…
In a Phase 3 clinical trial, Opsumit (macitentan) did not meet the study’s primary goal — improved exercise capacity — in patients with pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome, Actelion, the drug’s manufacturer, announced. Study results, however, will take time to interpret due to a “persistent placebo effect,”…
In a moderately sized group of patients with pulmonary hypertension (PH), nonsustained ventricular tachycardia (nsVT) occurred more often than previously reported, researchers said, and patients with PH group 1 seemed to be more at risk. Nonsustained ventricular tachycardia is an abnormally rapid ventricular rhythm, usually greater than 100 beats per…
A case report of a pulmonary arterial hypertension (PAH) patient who used an implanted hemodynamic monitor illustrates that improvements in pulmonary hemodynamics and right ventricle afterload with a “simple therapy” like oral iron supplements are both possible and measurable. The study, “Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension:…
PhaseBio Pharmaceuticals announced the closing of $14.7 million in a financing mechanism called convertible notes that will help it advance the clinical development of PB1046, its lead candidate to treat rare diseases of the heart and lungs, including pulmonary arterial hypertension (PAH). PB1046 is a vasoactive intestinal peptide (VIP) receptor agonist, being…
Scientists at Imperial College London have designed software that creates virtual 3-D versions of patients’ heart motion, helping doctors to determine likely outcomes in patients with pulmonary hypertension (PH) with greater accuracy, and possibly improve their treatment. The technology uses cardiac magnetic resonance imaging (MRI), blood tests, and other clinical observations, according to…
Pulmonary hypertension is a common outcome of bronchopulmonary dysplasia (BPD) in premature infants, with one in every or five pre-term babies with BPD going on to develop PH, a study reports. The study, “Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis,” showed that the odds ratio (the likelihood) of developing…
Women with high-risk congenital heart disease can safely become pregnant and give birth if they are carefully monitored and managed by doctors, according to a new scientific statement by the American Heart Association. “Management Of Pregnancy In Patients With Complex Congenital Heart Disease: A Scientific Statement For Healthcare Professionals…
